Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS National Non-Coverage Reversed For Electromagnetic Wound Therapy

This article was originally published in The Gray Sheet

Executive Summary

Diapulse's "plausible reasoning" that electromagnetic therapy falls under electrostimulation for chronic wound treatment helped convince CMS to reverse a national non-coverage policy for the indication

You may also be interested in...



E-Stim For Adjunctive Chronic Wound Therapy Does Not Meet TEC Criteria

A lack of high-quality clinical trials evaluating electrical stimulation or electromagnetic therapy for adjunctive chronic wound treatment has resulted in a failure to meet the BlueCross BlueShield Association Technology Evaluation Center's criteria

E-Stim For Adjunctive Chronic Wound Therapy Does Not Meet TEC Criteria

A lack of high-quality clinical trials evaluating electrical stimulation or electromagnetic therapy for adjunctive chronic wound treatment has resulted in a failure to meet the BlueCross BlueShield Association Technology Evaluation Center's criteria

Diapulse wound treatment system coverage

Non-thermal, pulsed electromagnetic energy wound treatment system Medicare coverage implementation begins July 6 following a national non-coverage policy reversal last December (1"The Gray Sheet" Dec. 22, 2003, p. 7). An HCPCS code has been established to cover adjunctive treatment in professional settings of chronic stage III or IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel